Results 151 to 160 of about 115,651 (262)

Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta‐analysis

Addiction, EarlyView.
Abstract Aim Our primary aim was to conduct a network meta‐analysis (NMA) for the effectiveness, safety and acceptability of all psychosocial interventions and all pharmacotherapies for cannabis use disorder (CUD). Methods We conducted a NMA of studies identified from two completed systematic reviews examining the effectiveness, safety and ...
Monika Halicka, Francesca Spiga, Tom P. Freeman, Suzanne Nielsen, Jelena Savović, Julian P. T. Higgins, Deborah M. Caldwell   +6 more
wiley   +1 more source

Synaptogyrin-3 plays a critical role in addiction-related dopamine dysfunction and behavioral maladaptations. [PDF]

Proc Natl Acad Sci U S A
Peck EG, Emerson SD, Curry AM, Holter KM, Estave PM, Sens JP, Colarusso OA, Farris SP, Kiraly DD, Gould RW, McCool BA, Calipari ES, Holleran KM, Jones SR.   +13 more
europepmc   +1 more source

A biological blind spot in addiction research: hormonal contraceptives and adolescent reward seeking. [PDF]

Neuropsychopharmacology
Seemiller LR, Crowley NA.
europepmc   +1 more source

Unlocking ‘stuckness’ and catalysing change: A qualitative study of clinician and service leader perspectives on psychedelic‐assisted therapy for substance use and mental health problems

Addiction, EarlyView.
Abstract Background and aims Australia recently down‐scheduled and authorised psychedelic‐assisted therapies, including psilocybin, for certain mental health conditions. Evidence is emerging for potential application in substance use disorder treatment. However, regulatory developments have outpaced implementation readiness.
Sarah J. Catchlove, Katrin Oliver, Michael Savic, Shalini Arunogiri   +3 more
wiley   +1 more source

A hybrid model based on vessel wall magnetic resonance imaging predicts recurrence in posterior circulation ischemic stroke: a multi-institutional study. [PDF]

J Neurointerv Surg
Wu Y, Zhang R, Liang X, Ju G, Li F, Hu T, Zheng B, Zhang L.   +7 more
europepmc   +1 more source

Identification of cannabis use disorder using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM‐5) versus DSM‐5‐proxy measures: Differences by socio‐demographic characteristics

Addiction, EarlyView.
Abstract Background and Aims Cannabis use disorder (CUD) is a pressing public health concern in the United States, and understanding trends in prevalence requires considerations of how changes in measurement influence identification of CUD. Starting in 2021, the National Survey on Drug Use and Health (NSDUH) assessed CUD using all 11 Diagnostic and ...
Evan L. Eschliman, Erin M. Annunziato, Nicole D. Fitzgerald, Pia M. Mauro   +3 more
wiley   +1 more source

Sex-specific neural activation to stress and alcohol cues in high-risk drinkers: links between orbitofrontal circuits, alcohol craving, and future drinking. [PDF]

Neuropsychopharmacology
Freeman C, Radoman M, Martins JS, Lacadie C, Seo D, Sinha R.   +5 more
europepmc   +1 more source

The evolution of Australian cannabis policies, 1967 to 2024

Addiction, EarlyView.
Abstract Aim To describe the outcomes of cannabis policy debates in Australia from 1967 to 2024. Methods We searched popular media, public reports, parliamentary inquiries and policy documents on cannabis in Australia since the 1960s and examined peer reviewed papers, national survey data and police records of cannabis‐related arrests.
Wayne D. Hall, Danielle Dawson, Ben Johnson, Tesfa M. Yimer   +3 more
wiley   +1 more source

Dissecting the role of mineralocorticoid receptors in binge-like alcohol drinking in mice: Finerenone as a potential pharmacotherapy. [PDF]

Psychopharmacology (Berl)
Wilkinson CS, Bruns N, Pince CL, McGinn MA, Farokhnia M, Leggio L, Vendruscolo LF.   +6 more
europepmc   +1 more source

Patient‐reported outcomes for monitoring substance use treatment: A systematic review of single‐item measures

Addiction, EarlyView.
Abstract Background and aims Measurement‐based care (MBC) is a structured approach using standardized, repeated assessments to monitor treatment progress and guide clinical decision‐making. MBC improves outcomes for substance use treatment but can be time consuming due in part to lengthy assessment tools. Single‐item, patient‐reported outcome measures (
Thomas J. Reese, Hilary A. Tindle, Justin Bachmann, Adam Wright, Jessica S. Ancker, Carolyn M. Audet, Mauli V. Shah, Bryan D. Steitz, Michael H. Levin, Kristopher A. Kast, David Marcovitz, Amanda von Horn, A. Taylor Kelley, John F. P. Bridges   +13 more
wiley   +1 more source